AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Cognitive Assessment Tools for Huntington's Disease.

Recruitingn/aAges 30 Years - 65 YearsAllOhio State University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. Genetic diagnosis of HD as defined by a CAG repeat size โ‰ฅ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form. Exclusion Criteria: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injuryโ€ฆ etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent.
๐Ÿ’Š

What it tests

  • Assessments
๐Ÿ“

Where

1 site
The Ohio State University Wexner Medical Center
Columbus, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy